GleamWall
中文EN

CGON CG Oncology, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1991792 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY183.6%
TTM net income YoY-56.8%
TTM EPS YoY-34.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-4,293.5%
Net margin-3,851.1%
FCF margin-3,068.0%
EBITDA margin-4,237.7%

Returns

ROE-28.3%
ROA-26.7%
ROIC (approx.)-26.0%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets5.3%
Debt / equity0.00x
Current ratio21.70x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-5.6%
Payout ratio—
Capex / revenue30.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.60M$1.16M$1.08M$2.32M$1.67M$0$52,000$456,000
Cost of revenue$2.67M———$1.58M———
Gross profit-$1.06M———$89,000———
R&D expense$39.22M$54.66M$43.73M$29.96M$27.88M$31.33M$27.47M$26.80M
SG&A expense$22.96M$28.98M$20.78M$17.99M$23.33M$17.41M$14.79M$11.71M
Operating income-$63.25M-$86.40M-$66.39M-$48.70M-$51.13M-$48.74M-$42.20M-$38.05M
Net income-$56.89M-$79.06M-$60.20M-$41.31M-$43.81M-$41.43M-$34.45M-$31.80M
EBITDA-$62.35M-$85.55M-$65.55M-$47.85M-$51.03M-$48.59M-$42.18M-$38.05M
EPS (basic)-0.64-0.90-0.71—-0.57-0.54-0.45—
EPS (diluted)-0.64-0.90-0.71—-0.57-0.54-0.45—
Weighted avg. shares (diluted)88.87M88.20M84.52M—76.73M76.23M76.19M—
Balance sheet
Cash & equivalents$28.25M$19.64M$33.70M$32.49M$45.15M$14.62M$41.47M$257.07M
Short-term investments$956.21M$1.01B$1.04B$709.66M$635.12M$646.43M$646.96M$484.93M
Receivables$666,000$417,000$1.27M$688,000$515,000——$0
Inventory$1.17M$1.00M$1.49M$1.56M$1.50M——$0
Current assets$1.01B$1.05B$1.10B$759.48M$695.79M$673.03M$701.19M$754.21M
PP&E, net$14.93M$14.71M$15.07M$15.60M$15.33M$253,000$264,000$272,000
Goodwill$10.30M$10.30M$10.30M$10.30M$12.80M——$0
Intangibles$530,000$545,000$560,000$575,000$1.67M——$0
Total assets$1.05B$1.09B$1.14B$791.59M$729.91M$701.45M$728.18M$754.80M
Current liabilities$46.43M$47.24M$35.22M$30.84M$30.53M$30.38M$22.64M$21.37M
Long-term debt$3.00M$3.00M$3.00M$3.00M$3.00M——$0
Total debt$3.00M$3.00M$3.00M$3.00M$3.00M——$0
Total liabilities$55.70M$56.54M$43.48M$38.99M$42.27M$31.09M$23.42M$21.42M
Shareholders' equity$990.97M$1.03B$1.09B$752.60M$687.64M$670.36M$704.76M$733.38M
Net debt-$25.25M-$16.64M-$30.70M-$29.49M-$42.15M——-$257.07M
Shares outstanding89.30M88.31M88.01M80.69M78.28M76.23M76.22M76.15M
Cash flow statement
Operating cash flow-$47.71M-$46.41M-$56.94M-$36.22M-$38.89M-$27.96M-$29.28M-$20.66M
Capital expenditure$1.11M$468,000$304,000$7,000$97,000$14,000$16,000$209,000
Free cash flow-$48.82M-$46.88M-$57.25M-$36.22M-$38.99M-$27.97M-$29.29M-$20.87M
Investing cash flow$46.03M$30.43M-$334.85M-$75.50M$15.04M$1.41M-$186.77M$10.90M
Financing cash flow$10.28M$1.92M$393.00M$99.07M$54.37M-$296,000$450,000$223.41M
Depreciation & amortization$900,000$850,000$841,000$849,000$100,000$156,000$24,000$0
Stock-based compensation$8.46M$14.33M$6.47M$7.19M$7.33M$7.01M$5.15M$4.99M

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.